Macrophage requirements for abatacept response in rheumatoid arthritis
Authors' conclusion
ABA response in RA patients is associated with a particular pro-inflammatory macrophage phenotype pre-treatment and IDO is required for ABA effect.
Study context
- Population
- Rheumatoid arthritis (RA) patients treated with ABA; monocyte-derived macrophages from healthy donors (in vitro)
- Comparison
- ABA good responders vs non-responders; ABA vs no ABA
- Outcome
- Biomarkers of ABA response and involvement of IDO
- Follow-up
- 6 months
Methodological detailsin vitro co-culture assay
- In vitro co-culture assay
Main finding
As reported in the abstract
- Pre-treatment frequency of CD16- CD64+ CD86high macrophages increased in ABA good responders vs non-responders
- ABA seemed to increase IDO production
- In vitro, ABA reduced proliferation of T cells activated by anti-CD3 and GM-CSF+LPS+IFN-γ macrophages
- Inhibitory effect of ABA abolished by IDO blockade
Original publication
Macrophage requirements for abatacept response in rheumatoid arthritis. Clin Exp Rheumatol. Published 30 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →